Novartis
NEWS
Moderna will leverage AbCellera’s AI-powered technology to search and analyze natural immune responses in the hopes of identifying antibodies for up to six targets.
Replicate focuses on using self-replicating RNA (srRNA) to develop therapies for autoimmune and inflammatory diseases and prevent drug resistance in cancer.
The oncogenicity and neurotoxicity risks of AAVs and possible mitigation strategies were the primary focus on Thursday.
Novartis announced that it is discontinuing the trial in kidney transplant patients after conducting an interim analysis from its CIRRUS-1 trial of CFZ533 (iscalimab).
There were a fair number of clinical trial announcements last week. Here’s a look.
BioLabs is opening its next hub in Dallas in a 37,000-square-foot flexible life science facility. The Biotech+ Hub can accommodate 35 startups, for which it’s now accepting applications.
Newly launched Versanis Bio is aiming to turn a Novartis drug that was once developed to help with muscle loss and weakness into an anti-obesity treatment.
A new study on COVID-19 behavior has found that patients affected by the virus might have died due to a buildup of coronavirus directly in the lungs and not because of a secondary infection.
Novartis reported that its Kymriah failed to hit its primary endpoint in the Phase III BELINDA trial in aggressive B-cell non-Hodgkin lymphoma after relapse or lack of response to first-line treatment.
JOBS
IN THE PRESS